Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	10.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Problems Go Beyond Poor Profit

Nov 04

There's Reason For Concern Over Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Massive 51% Price Jump

Oct 14

Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

May 06

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Apr 12

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Mar 22

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Mar 07

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Feb 20

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Feb 07

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Jan 25

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Jan 12

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Dec 28

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Dec 15

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Dec 03

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 21

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:1349 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	692	105	-20	9	N/A
6/30/2024	736	111	154	207	N/A
3/31/2024	809	102	217	275	N/A
12/31/2023	851	109	-28	71	N/A
9/30/2023	1,023	191	-107	-29	N/A
6/30/2023	1,283	242	-85	-3	N/A
3/31/2023	1,080	142	-72	22	N/A
12/31/2022	1,031	138	78	165	N/A
9/30/2022	1,158	132	185	318	N/A
6/30/2022	1,013	112	142	272	N/A
3/31/2022	1,155	213	128	276	N/A
12/31/2021	1,140	213	149	269	N/A
9/30/2021	1,036	198	139	241	N/A
6/30/2021	997	201	28	108	N/A
3/31/2021	925	188	11	66	N/A
12/31/2020	834	165	71	113	N/A
9/30/2020	901	191	120	151	N/A
6/30/2020	874	165	197	229	N/A
3/31/2020	980	204	N/A	N/A	N/A
12/31/2019	1,029	227	229	269	N/A
9/30/2019	848	151	174	217	N/A
6/30/2019	837	151	220	261	N/A
3/31/2019	678	91	N/A	N/A	N/A
12/31/2018	742	112	141	180	N/A
9/30/2018	632	95	69	110	N/A
6/30/2018	521	78	N/A	41	N/A
3/31/2018	510	77	N/A	42	N/A
12/31/2017	498	75	N/A	43	N/A
9/30/2017	575	109	N/A	80	N/A
6/30/2017	652	142	N/A	117	N/A
3/31/2017	637	141	N/A	129	N/A
12/31/2016	622	139	N/A	141	N/A
9/30/2016	615	136	N/A	131	N/A
6/30/2016	607	134	N/A	121	N/A
3/31/2016	593	131	N/A	109	N/A
12/31/2015	579	128	N/A	96	N/A
9/30/2015	556	125	N/A	102	N/A
6/30/2015	532	122	N/A	107	N/A
3/31/2015	501	120	N/A	98	N/A
12/31/2014	471	118	N/A	88	N/A
9/30/2014	464	111	N/A	N/A	N/A
6/30/2014	412	96	N/A	105	N/A
3/31/2014	446	98	N/A	N/A	N/A
12/31/2013	416	87	N/A	89	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1349's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 1349's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1349's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1349's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1349's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1349's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 16:18
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Hu	Deutsche Bank
Feng Qiang Sun	Guotai Junan International Holdings Limited
Xiang Jun	Industrial Securities Co. Ltd.

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Supplemental Announcement Related to Earnings Guidance for the Six Months Ended 30 June 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Problems Go Beyond Poor Profit

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.014 (vs CN¥0.021 in 3Q 2023)

There's Reason For Concern Over Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Massive 51% Price Jump

Investor sentiment deteriorates as stock falls 39%

Now 59% overvalued after recent price rise

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 21%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Phase II Clinical Trial in the United States of Hemoporfin for Injection for the Treatment of Port Wine Birthmark

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Phase III Clinical Trial of FDA018 Antibody Drug Conjugate for Injection for the Treatment of Triple Negative Breast Cancer

Upcoming dividend of HK$0.022 per share

Second quarter 2024 earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. announces Annual dividend, payable on October 10, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient in Phase I Clinical Trial of Fz-Ad005 Antibody Drug Conjugate for Injection

Upcoming dividend of CN¥0.07 per share

Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders

First quarter 2024 earnings released

Now 21% overvalued

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Aug 15, 2024

Full year 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in FY 2022)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug

Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.11 in 3Q 2022)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors

Less than half of directors are independent

Upcoming dividend of CN¥0.07 per share at 2.7% yield

First quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.005 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in FY 2021)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Indicative Announcement-First Patient Enrolled in Phase I Clinical Trial of FDA022 Antibody Drug Conjugate for Injection for the Treatment of Advanced Solid Tumors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issue by the National Medical Products Administration of the PRC

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.046 in 3Q 2021)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q3, 2022 Results on Oct 27, 2022

Second quarter 2022 earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces Supplemental Announcement Related to Earnings Guidance for the Six Months Ended 30 June 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Received the Acceptance Notice of the Quality and Efficacy Consistency Evaluation of Generic Drugs for Chemical Injection

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Approves Final Dividend for the Year Ended 31 December 2021, Payable on or Before 26 August 2022

Upcoming dividend of CN¥0.07 per share

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives the Acceptance Notice Issued by the National Medical Products Administration of the Prc

First quarter 2022 earnings released

Less than half of directors are independent

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Full year 2021 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in FY 2020)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 26 August 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥0.058 (vs CN¥0.045 in 2Q 2020)

Upcoming dividend of CN¥0.05 per share

First quarter 2021 earnings released

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Full year 2020 earnings released

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

New 90-day high: HK$4.67

Investor sentiment improved over the past week

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Third quarter earnings released

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 29, 2020

New 90-day low: HK$3.65

New 90-day low - HK$4.10

New 90-day low - HK$4.95

Earnings released